Report Detail
Global (United States, European Union and China) Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2019-2025
- RnM3665549 |
- 13 August, 2019 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
In 2019, the market size of Benign Prostatic Hyperplasia (BPH) Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Benign Prostatic Hyperplasia (BPH) Drugs.
This report studies the global market size of Benign Prostatic Hyperplasia (BPH) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Benign Prostatic Hyperplasia (BPH) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Market Segment by Product Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors
Market Segment by Application
Men
Women
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Benign Prostatic Hyperplasia (BPH) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia (BPH) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Alpha-Blocker
- 1.3.3 Phosphodiesterase Type-5 Inhibitors
- 1.3.4 5-Alpha-Reductase Inhibitors
- 1.4 Market Segment by Application
- 1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2019-2025)
- 1.4.2 Men
- 1.4.3 Women
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size
- 2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2014-2025
- 2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2014-2025
- 2.2 Benign Prostatic Hyperplasia (BPH) Drugs Growth Rate by Regions
- 2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions 2014-2019
- 2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
- 3.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturers
- 3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
- 3.6 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Alpha-Blocker Sales and Revenue (2014-2019)
- 4.1.2 Phosphodiesterase Type-5 Inhibitors Sales and Revenue (2014-2019)
- 4.1.3 5-Alpha-Reductase Inhibitors Sales and Revenue (2014-2019)
- 4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type
- 4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type
- 4.4 Benign Prostatic Hyperplasia (BPH) Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
6 United States
- 6.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
- 6.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
- 6.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
- 7.2 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
- 7.3 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application
8 China
- 8.1 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
- 8.2 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
- 8.3 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
- 9.2 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
- 9.3 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application
- 9.4 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
- 9.4.2 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Astellas Pharma
- 10.1.1 Astellas Pharma Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.1.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.1.5 Astellas Pharma Recent Development
- 10.2 Eli Lilly
- 10.2.1 Eli Lilly Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.2.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.2.5 Eli Lilly Recent Development
- 10.3 GlaxoSmithKline
- 10.3.1 GlaxoSmithKline Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.3.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.3.5 GlaxoSmithKline Recent Development
- 10.4 Sanofi
- 10.4.1 Sanofi Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.4.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.4.5 Sanofi Recent Development
- 10.5 ADC Therapeutics
- 10.5.1 ADC Therapeutics Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.5.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.5.5 ADC Therapeutics Recent Development
- 10.6 Bayer HealthCare
- 10.6.1 Bayer HealthCare Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.6.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.6.5 Bayer HealthCare Recent Development
- 10.7 Bristol-Myers Squibb
- 10.7.1 Bristol-Myers Squibb Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.7.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.7.5 Bristol-Myers Squibb Recent Development
- 10.8 Valeant Pharmaceuticals
- 10.8.1 Valeant Pharmaceuticals Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.8.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.8.5 Valeant Pharmaceuticals Recent Development
- 10.9 Endo Pharmaceuticals
- 10.9.1 Endo Pharmaceuticals Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.9.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.9.5 Endo Pharmaceuticals Recent Development
- 10.10 Foresee Pharmaceuticals
- 10.10.1 Foresee Pharmaceuticals Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
- 10.10.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
- 10.10.5 Foresee Pharmaceuticals Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
- 11.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
- 11.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
12 Market Forecast
- 12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type
- 12.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application
- 12.4 Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions
- 12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on BenignProstaticHyperplasia(BPH)Drugs. Industry analysis & Market Report on BenignProstaticHyperplasia(BPH)Drugs is a syndicated market report, published as Global (United States, European Union and China) Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of BenignProstaticHyperplasia(BPH)Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
